Cargando…
Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients
In a prospective cohort study 8466 women attending routine cervical cancer screening were recruited. Colposcopy was performed on women with any degree of atypia on cytology and/or a positive high-risk human papillomavirus (HPV)-DNA test (HC2; Hybrid Capture 2(©)), and for a randomly selected sample...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377109/ https://www.ncbi.nlm.nih.gov/pubmed/12771924 http://dx.doi.org/10.1038/sj.bjc.6600918 |
_version_ | 1782154779558936576 |
---|---|
author | Petry, K-U Menton, S Menton, M van Loenen-Frosch, F de Carvalho Gomes, H Holz, B Schopp, B Garbrecht-Buettner, S Davies, P Boehmer, G van den Akker, E Iftner, T |
author_facet | Petry, K-U Menton, S Menton, M van Loenen-Frosch, F de Carvalho Gomes, H Holz, B Schopp, B Garbrecht-Buettner, S Davies, P Boehmer, G van den Akker, E Iftner, T |
author_sort | Petry, K-U |
collection | PubMed |
description | In a prospective cohort study 8466 women attending routine cervical cancer screening were recruited. Colposcopy was performed on women with any degree of atypia on cytology and/or a positive high-risk human papillomavirus (HPV)-DNA test (HC2; Hybrid Capture 2(©)), and for a randomly selected sample of 3.4% women with negative findings on both. Quality control included reviews of cytology, histology, colposcopy images and retesting of samples with polymerase chain reaction. Test diagnostic performances were based on 7908 women who had complete baseline and follow-up results. Routine histology identified 86 women with high-grade cervical intraepithelial neoplasia (CIN2+), which was confirmed by review histology in only 46 cases. Sensitivity of routine cytology for the detection of CIN2+ was 43.5%, with a specificity, positive predictive value (PPV), negative predictive value (NPV) of 98.0, 11.4 and 99.7%, respectively. Sensitivity of the HC2 test for the detection of CIN2+ was 97.8%, with a specificity, PPV and NPV, of 95.3, 10.9 and 100%, respectively. No high-grade neoplasia was detected in the randomly selected control group. A negative HPV-test result, even in combination with a positive Papanicolaou (Pap) result, virtually excluded any risk of underlying high-grade disease, but this was not the case for a negative Pap result. These data show that HPV testing is of value for the detection or exclusion of prevalent CIN in a routine cervical cancer-screening setting and could be used for further risk classification of women for follow-up management. |
format | Text |
id | pubmed-2377109 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2003 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23771092009-09-10 Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients Petry, K-U Menton, S Menton, M van Loenen-Frosch, F de Carvalho Gomes, H Holz, B Schopp, B Garbrecht-Buettner, S Davies, P Boehmer, G van den Akker, E Iftner, T Br J Cancer Molecular and Cellular Pathology In a prospective cohort study 8466 women attending routine cervical cancer screening were recruited. Colposcopy was performed on women with any degree of atypia on cytology and/or a positive high-risk human papillomavirus (HPV)-DNA test (HC2; Hybrid Capture 2(©)), and for a randomly selected sample of 3.4% women with negative findings on both. Quality control included reviews of cytology, histology, colposcopy images and retesting of samples with polymerase chain reaction. Test diagnostic performances were based on 7908 women who had complete baseline and follow-up results. Routine histology identified 86 women with high-grade cervical intraepithelial neoplasia (CIN2+), which was confirmed by review histology in only 46 cases. Sensitivity of routine cytology for the detection of CIN2+ was 43.5%, with a specificity, positive predictive value (PPV), negative predictive value (NPV) of 98.0, 11.4 and 99.7%, respectively. Sensitivity of the HC2 test for the detection of CIN2+ was 97.8%, with a specificity, PPV and NPV, of 95.3, 10.9 and 100%, respectively. No high-grade neoplasia was detected in the randomly selected control group. A negative HPV-test result, even in combination with a positive Papanicolaou (Pap) result, virtually excluded any risk of underlying high-grade disease, but this was not the case for a negative Pap result. These data show that HPV testing is of value for the detection or exclusion of prevalent CIN in a routine cervical cancer-screening setting and could be used for further risk classification of women for follow-up management. Nature Publishing Group 2003-05-19 2003-05-13 /pmc/articles/PMC2377109/ /pubmed/12771924 http://dx.doi.org/10.1038/sj.bjc.6600918 Text en Copyright © 2003 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Molecular and Cellular Pathology Petry, K-U Menton, S Menton, M van Loenen-Frosch, F de Carvalho Gomes, H Holz, B Schopp, B Garbrecht-Buettner, S Davies, P Boehmer, G van den Akker, E Iftner, T Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients |
title | Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients |
title_full | Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients |
title_fullStr | Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients |
title_full_unstemmed | Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients |
title_short | Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients |
title_sort | inclusion of hpv testing in routine cervical cancer screening for women above 29 years in germany: results for 8466 patients |
topic | Molecular and Cellular Pathology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377109/ https://www.ncbi.nlm.nih.gov/pubmed/12771924 http://dx.doi.org/10.1038/sj.bjc.6600918 |
work_keys_str_mv | AT petryku inclusionofhpvtestinginroutinecervicalcancerscreeningforwomenabove29yearsingermanyresultsfor8466patients AT mentons inclusionofhpvtestinginroutinecervicalcancerscreeningforwomenabove29yearsingermanyresultsfor8466patients AT mentonm inclusionofhpvtestinginroutinecervicalcancerscreeningforwomenabove29yearsingermanyresultsfor8466patients AT vanloenenfroschf inclusionofhpvtestinginroutinecervicalcancerscreeningforwomenabove29yearsingermanyresultsfor8466patients AT decarvalhogomesh inclusionofhpvtestinginroutinecervicalcancerscreeningforwomenabove29yearsingermanyresultsfor8466patients AT holzb inclusionofhpvtestinginroutinecervicalcancerscreeningforwomenabove29yearsingermanyresultsfor8466patients AT schoppb inclusionofhpvtestinginroutinecervicalcancerscreeningforwomenabove29yearsingermanyresultsfor8466patients AT garbrechtbuettners inclusionofhpvtestinginroutinecervicalcancerscreeningforwomenabove29yearsingermanyresultsfor8466patients AT daviesp inclusionofhpvtestinginroutinecervicalcancerscreeningforwomenabove29yearsingermanyresultsfor8466patients AT boehmerg inclusionofhpvtestinginroutinecervicalcancerscreeningforwomenabove29yearsingermanyresultsfor8466patients AT vandenakkere inclusionofhpvtestinginroutinecervicalcancerscreeningforwomenabove29yearsingermanyresultsfor8466patients AT iftnert inclusionofhpvtestinginroutinecervicalcancerscreeningforwomenabove29yearsingermanyresultsfor8466patients |